Expert Design Support

Drawing on our experience of leading and managing multi-disciplinary drug discovery project teams, we can work with clients to:

  • Optimise screening sequences to ensure they are fit for purpose and can enable delivery of high-quality candidate molecules
  • Apply cutting-edge techniques such as chemical proteomics and design of activity-based probes to understand the biology of a given target or molecule
  • Apply virtual screening and file-mining approaches to identify novel hit matter
  • Analyse output from high-throughput screens, triaging clusters of hits and identifying promising starting points using parameters such as ligand efficiency, lipophilic efficiency, ADME properties, off-target activity, binding mode, scope for modification and IP analysis
  • Follow up screening hits rapidly to generate lead series with demonstrable structure-activity relationships; develop an understanding of the risks that each template presents to allow efficient decision making in terms of series progression or termination
  • Optimise lead series using an holistic approach to deliver preclinical candidates that meet required biological, ADME, Pharm Sci and drug-safety properties
We have worked on projects with a wide variety of requirements e.g.
  • Designing molecules to cross the blood-brain barrier whilst retaining drug-like properties
  • Designing molecules to be peripherally restricted whilst retaining oral absorption
  • Identifying and designing kinase inhibitors with slow binding kinetics
  • Designing molecules that can be delivered by inhaled or topical routes that show a long duration of action and high therapeutic index
and targets from many gene families e.g.
  • Enzymes (including phosphodiesterases, metalloproteinases, kinases, histone demethylases and acetylases)
  • GPCRs (aminergic, peptidergic, class B); agonists, partial agonists, antagonists, inverse agonists, orthosteric and allosteric binders
  • Nuclear hormone receptors
  • Ligand- and voltage-gated ion channels
  • Monoamine transporters
  • Protein-protein interactions
for a number of disease areas e.g.
  • Allergy and Respiratory
  • Anti-viral and Anti-fungal Diseases
  • CNS Disorders
  • Gastrointestinal
  • Genitourinary
  • Parasitic Diseases
  • Obesity
  • Oncology
  • Pain
  • Regenerative Medicine
  • Tissue Repair

LinkedIn  Sandexis Medicinal Chemistry Ltd 2015
Company No. 07767700
Postal address: Innovation House, Discovery Park, Ramsgate Road, Sandwich, Kent, CT13 9ND, UK
Business registered address: 45 Queen Street, Deal, Kent, CT14 6EY, UK